{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:22:32Z","timestamp":1783617752045,"version":"3.55.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study aimed to investigate whether the introduction of\n                      <jats:bold>\u03b2<\/jats:bold>\n                      -lactamase inhibitors (BLIs) alters the adverse event (AE) profiles of parent penicillin antibiotics, using real-world pharmacovigilance data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A disproportionality analysis was conducted using reports from the FDA Adverse Event Reporting System database (2004\u20132024). The research compared the safety profiles of amoxicillin versus amoxicillin-clavulanate (ACP) and ampicillin versus ampicillin-sulbactam (ASS) by employing multiple statistical methods, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM). The signals were considered significant only when meeting multiple algorithm criteria (Reporting Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, Empirical Bayesian Geometric Mean). Subgroup analyses by age and gender were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analysis of over 200,000 reports revealed distinct AE spectra. ACP demonstrated a significantly stronger association with hepatobiliary disorders (e.g., drug-induced liver injury, ROR 35.41) compared to amoxicillin alone (ROR 4.98). In contrast, amoxicillin monotherapy showed stronger signals for certain immune-mediated skin reactions. For ampicillin, monotherapy was strongly linked to pregnancy\/perinatal events, whereas ASS showed higher risks for gastrointestinal disorders (e.g., hemorrhagic enterocolitis), specific skin reactions, and allergic events. Subgroup analyses indicated that hepatobiliary and renal risks with ACP were more prominent in males and the elderly (\u226560 years), while severe skin reactions with ampicillin were more frequent in females.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The addition of BLIs significantly may modify the AE profiles of parent penicillins, introducing distinct organ-specific risks. These findings underscore the necessity for personalized risk assessment and monitoring in clinical practice, tailored to the specific combination agent and patient demographics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1772354","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:48:53Z","timestamp":1773384533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Will the introduction of \u03b2-lactamase inhibitors alter the adverse event profile of parent penicillins antibiotics? a pharmacovigilance study based on amoxicillin-clavulanate and ampicillin-sulbactam"],"prefix":"10.3389","volume":"17","author":[{"given":"Yanlang","family":"He","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, Shaoyang Central Hospital","place":["Shaoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Shaoyang Central Hospital","place":["Shaoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guie","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Shaoyang Central Hospital","place":["Shaoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinghui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Shaoyang Central Hospital","place":["Shaoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Shaoyang Central Hospital","place":["Shaoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of General Medicine, the Second Affiliated Hospital of Wannan Medical College","place":["Wuhu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.3390\/molecules30183825","article-title":"Hepatotoxicity and antimicrobial resistance to amoxicillin and amoxicillin\/clavulanic acid: data analysis from EudraVigilance","volume":"30","author":"Ammendolia","year":"2025","journal-title":"Molecules"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1111\/all.14298","article-title":"Characterization of amoxicillin and clavulanic acid specific T-cell clones from patients with immediate drug hypersensitivity","volume":"75","author":"Ariza","year":"2020","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-Lactams and \u03b2-Lactamase inhibitors: an overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ajog.2020.09.044","article-title":"Management of clinical chorioamnionitis: an evidence-based approach","volume":"223","author":"Conde-Agudelo","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","article-title":"Acute and clinically relevant drug-induced liver injury: a population based case-control study","volume":"58","author":"de Abajo","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1007\/s10620-016-4121-6","article-title":"Amoxicillin-clavulanate-induced liver injury","volume":"61","author":"deLemos","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cll.2004.03.003","article-title":"Evolution of amoxicillin\/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns","volume":"24","author":"File","year":"2004","journal-title":"Clin. Lab. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clp.2024.10.002","article-title":"Neonatal early-onset sepsis: epidemiology, microbiology, and controversies in practice","volume":"52","author":"Flannery","year":"2025","journal-title":"Clin. Perinatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/cei.12558","article-title":"Comparative analysis of portal hepatic infiltrating leukocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis","volume":"180","author":"Foureau","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/archinte.1996.00440110099013","article-title":"Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid","volume":"156","author":"Garc\u00eda Rodr\u00edguez","year":"1996","journal-title":"Arch. Intern Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1093\/infdis\/jiw402","article-title":"Interplay between antibiotic resistance and virulence during disease promoted by multidrug-resistant bacteria","volume":"215","author":"Geisinger","year":"2017","journal-title":"J. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0140-6736(05)17907-0","article-title":"Outpatient antibiotic use in Europe and association with resistance: a cross-national database study","volume":"365","author":"Goossens","year":"2005","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ajic.2015.05.020","article-title":"Retrospective cohort study of inappropriate piperacillin-tazobactam use for lower respiratory tract and skin and soft tissue infections: opportunities for antimicrobial stewardship","volume":"43","author":"Havey","year":"2015","journal-title":"Am. J. Infect. Control"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1713170","DOI":"10.3389\/fphar.2025.1713170","article-title":"Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database","volume":"16","author":"He","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/antibiotics11111505","article-title":"Comparative effectiveness of ampicillin\/sulbactam versus cefazolin as targeted therapy for bacteremia caused by beta-lactamase-producing methicillin-sensitive staphylococcus aureus: a single-center retrospective study","volume":"11","author":"Hirai","year":"2022","journal-title":"Antibiot. (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.yrtph.2014.09.007","article-title":"Age-related differences in reporting of drug-associated liver injury: data-mining of WHO safety report database","volume":"70","author":"Hunt","year":"2014","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e5768","DOI":"10.1002\/pds.5768","article-title":"Adverse drug reaction signal detection methods in spontaneous reporting system: a systematic review","volume":"33","author":"Jiao","year":"2024","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"107228","DOI":"10.1016\/j.bpc.2024.107228","article-title":"Metallo-\u03b2-lactamase inhibitors: a continuing challenge for combating antibiotic resistance","volume":"309","author":"Kang","year":"2024","journal-title":"Biophys. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/1471-0528.17073","article-title":"Listeriosis in pregnancy: an umbrella review of maternal exposure, treatment and neonatal complications","volume":"129","author":"Khsim","year":"2022","journal-title":"BJOG"},{"key":"B21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/0029-7844(95)00181-P","article-title":"Latency period after preterm premature rupture of membranes: a comparison of ampicillin with and without sulbactam","volume":"86","author":"Lewis","year":"1995","journal-title":"Obstet. Gynecol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","article-title":"Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance","volume":"44","author":"Mascolo","year":"2021","journal-title":"Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/s0002-9378(96)70154-0","article-title":"The effect of timing of single-dose transplacental ampicillin-sulbactam therapy for prevention of neonatal group B streptococcal colonization and bacteremia in a rabbit model","volume":"175","author":"McDuffie","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"109015","DOI":"10.1016\/j.intimp.2022.109015","article-title":"Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: a real-world study of the FDA adverse event reporting system","volume":"110","author":"Moore","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"w20503","DOI":"10.4414\/smw.2021.20503","article-title":"Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase\u2122 from 2010 to 2020","volume":"151","author":"Ortland","year":"2021","journal-title":"Swiss Med. Wkly."},{"key":"B27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1055\/s-2007-994485","article-title":"Ampicillin\/sulbactam versus ampicillin alone for cesarean section prophylaxis: a randomized double-blind trial","volume":"12","author":"Rijhsinghani","year":"1995","journal-title":"Am. J. Perinatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol","volume":"13","author":"Rothman","year":"2004","journal-title":"Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jaip.2017.02.007","article-title":"Patients taking amoxicillin-clavulanic can become simultaneously sensitized to both drugs","volume":"5","author":"Salas","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jac\/dkm111","article-title":"Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy","volume":"60","author":"Salvo","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1517\/14740330802527984","article-title":"Amoxicillin and amoxicillin plus clavulanate: a safety review","volume":"8","author":"Salvo","year":"2009","journal-title":"Expert Opin. Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1001\/jama.2023.15503","article-title":"Treatment failure and adverse events after amoxicillin-clavulanate vs amoxicillin for pediatric acute sinusitis","volume":"330","author":"Savage","year":"2023","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in parp inhibitors: a real-world study using fda adverse event reporting system (faers) database","volume":"12","author":"Shu","year":"2022","journal-title":"Cancer Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jox15050144","article-title":"Adverse event signals associated with beta-lactamase inhibitors: disproportionality analysis of USFDA adverse event reporting system","volume":"15","author":"Sridharan","year":"2025","journal-title":"J. Xenobiot."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e68111","DOI":"10.1371\/journal.pone.0068111","article-title":"HLA alleles influence the clinical signature of amoxicillin\u2013clavulanate hepatotoxicity","volume":"8","author":"Stephens","year":"2013","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1538881","DOI":"10.3389\/fphar.2025.1538881","article-title":"Signal detection and safety analysis of three tyrosine kinase inhibitors for HER-2 positive breast cancer: a retrospective study based on the FAERS database","volume":"16","author":"Tang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4168\/aair.2023.15.2.201","article-title":"Clavulanic acid is a leading culprit beta-lactam in immediate allergic reactions to penicillins","volume":"15","author":"Torres-Rojas","year":"2023","journal-title":"Allergy Asthma Immunol. Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"104572","DOI":"10.1016\/j.bjid.2025.104572","article-title":"Indications and prescriptions of penicillins in a population of Colombia: a cross-sectional study","volume":"29","author":"Valladales-Restrepo","year":"2025","journal-title":"Braz J. Infect. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/jac\/dkh050","article-title":"Augmentin (Amoxicillin\/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent","volume":"53","author":"White","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e939258","DOI":"10.12659\/AOT.939258","article-title":"Breaking antimicrobial resistance: high-dose amoxicillin with clavulanic acid for urinary tract infections due to extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae","volume":"28","author":"Wilkowski","year":"2023","journal-title":"Ann. Transpl."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00228-025-03872-0","article-title":"Post-marketing safety signals of imatinib: pharmacovigilance insights from the FDA adverse event reporting system (FAERS) and implications for clinical practice","volume":"81","author":"Xia","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2147\/IDR.S296233","article-title":"In vitro effect of the combination of aztreonam and amoxicillin\/clavulanic acid against carbapenem-resistant gram-negative organisms producing Metallo-\u03b2-Lactamase","volume":"14","author":"Xu","year":"2021","journal-title":"Infect. Drug Resist"},{"key":"B43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/DMSO.S348025","article-title":"Difference in gastrointestinal risk associated with use of GLP-1 receptor agonists: a real-world pharmacovigilance study","volume":"15","author":"Zhou","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"B44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/1471-2334-10-341","article-title":"Ampicillin\/sulbactam versus cefuroxime as antimicrobial prophylaxis for cesarean delivery: a randomized study","volume":"10","author":"Ziogos","year":"2010","journal-title":"BMC Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1772354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:48:54Z","timestamp":1773384534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1772354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":44,"alternative-id":["10.3389\/fphar.2026.1772354"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1772354","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1772354"}}